COMP <GO>
ZBH vs ABBV // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Zimmer Biomet Holdings Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ZBH 6
— ABBV 9
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: ZBH
LAST: $94.52 (-3.03%) • MKT CAP: $18.59B
options-implied-move
7.00%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
options-implied-move
7.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZBH VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ZBH | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.70% | 70.20% | -0.50 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.60% | 29.00% | -24.40 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.3x | 33.3x | -14.00 | ZBH | /valuation <GO> |
| Free Cash Flow Yield | 7.92% | 3.47% | +4.45 | ZBH | /fcf-yield <GO> |
| Operating Margin | 13.30% | 24.60% | -11.30 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 8.60% | 6.90% | +1.70 | ZBH | /net-margins <GO> |
| Revenue Growth (YoY) | 7.20% | 8.60% | -1.40 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.02% | 2.27% | -1.25 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.42 | 5.33 | -2.91 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | ZBH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 7.00% | 7.40% | -0.40 | ZBH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.8 | 72.8 | -23.01 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.02 | 1.15 | -0.13 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.6x | 113.1x | -88.50 | ZBH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $18.59B | $513.86B | -$495.27B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ZBH REV | ABBV REV | ZBH GROSS % | ABBV GROSS % | ZBH FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.23B | $61.16B | 69.7% | 70.2% | $1.47B | $17.82B |
| FY 2024 | $7.68B | $56.33B | 71.5% | 70.0% | $1.30B | $17.83B |
| FY 2023 | $7.39B | $54.32B | 44.0% | 44.0% | $1.25B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZBH // BETA 1.02
ABBV // BETA 1.15